SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

ECG Interpretation: Everything You Need to Know to Understand and In…

Houston Methodist DeBakey Heart and Vascular Center

A. Dave

EHRA 2024: Ongoing Clinical Investigations with Cardiac Contractilit…

CCM® Therapy

N. Varma

EHRA 2024: Real-World Experience with Cardiac Contractility Modulati…

CCM® Therapy

J. Kuschyk

EHRA 2024: Cardiac Contractility Modulation: Innovative Therapy for …

CCM® Therapy

V. Reddy, N. Varma, K. Kuck, J. Kuschyk, N. Aspromonte

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

The Past, Present and Future of the Total Artificial Heart

The Texas Heart Institute

W. Cohn, O. Frazier

The Best of AHA23 for the Primary Care Doctor

Cecilia Bahit

EHRA 2024: Unmet Medical Needs in Heart Failure Management: Can Devi…

CCM® Therapy

N. Aspromonte

EHRA 2024: Cardiac Contractility Modulation: Innovation Therapy for …

CCM® Therapy

K. Kuck, J. Kuschyk, V. Reddy, N. Aspromonte, N. Varma

Heart Failure Case Presentations

San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians

B. Greenberg, G. Fonarow, N. Wettersten, M. Rosa Costanzo

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

Mary E. Money

ATS 2023 Insights: To PAP or Not to PAP - Heart Failure and Sleep Di…

Vaishnavi Kundel

V. Kundel

Classification, Diagnosis and Management of Pulmonary Hypertension: …

Icahn School of Medicine at Mount Sinai

R. Benza

Implementation of Drug Therapies for Heart Failure with Reduced Ejec…

Michigan Medicine

J. Golbus